464 related articles for article (PubMed ID: 27116326)
1. Duration of dual antiplatelet therapy after various drug-eluting stent implantation.
Sharma A; Sharma SK; Vallakati A; Garg A; Lavie CJ; Mukherjee D; Marmur JD
Int J Cardiol; 2016 Jul; 215():157-66. PubMed ID: 27116326
[TBL] [Abstract][Full Text] [Related]
2. The optimal discontinuation of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention with drug-eluting stents: A meta-analysis of randomized trials.
Wang W; Liu J; Fang J; Liu Y; An T; Zou M; Cheng G
Int J Cardiol; 2017 May; 235():73-86. PubMed ID: 28284499
[TBL] [Abstract][Full Text] [Related]
3. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
4. Duration of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation in Diabetic and Non-Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Sharma A; Garg A; Elmariah S; Drachman D; Obiagwu C; Vallakati A; Sharma SK; Lavie CJ; Mukherjee D; Waksman R; Stefanini GG; Feres F; Marmur JD; Helft G
Prog Cardiovasc Dis; 2018; 60(4-5):500-507. PubMed ID: 29277295
[TBL] [Abstract][Full Text] [Related]
5. Optimal Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents: Meta-Analysis of Randomized Trials.
Abo-Salem E; Alsidawi S; Jamali H; Effat M; Helmy T
Cardiovasc Ther; 2015 Oct; 33(5):253-63. PubMed ID: 26010419
[TBL] [Abstract][Full Text] [Related]
6. Duration of dual antiplatelet therapy following drug-eluting stent implantation: A systemic review and meta-analysis of randomized controlled trials with longer follow up.
Sharma A; Agrawal S; Garg A; Vallakati A; Lavie CJ; Helft G
Catheter Cardiovasc Interv; 2017 Jul; 90(1):31-37. PubMed ID: 28557264
[TBL] [Abstract][Full Text] [Related]
7. Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
Yu X; Chen F; He J; Gao Y; Wu C; Luo Y; Zhang X; Zhang Y; Ren X; Lv S
Coron Artery Dis; 2013 May; 24(3):217-23. PubMed ID: 23425771
[TBL] [Abstract][Full Text] [Related]
8. Duration of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Sharma A; Hai O; Garg A; Vallakati A; Lavie CJ; Marmur JD
Curr Probl Cardiol; 2017 Dec; 42(12):404-417. PubMed ID: 29110813
[TBL] [Abstract][Full Text] [Related]
9. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
; Bittl JA; Baber U; Bradley SM; Wijeysundera DN
Circulation; 2016 Sep; 134(10):e156-78. PubMed ID: 27026019
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.
Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Sabaté M; Smits PC; Kaiser C; D'Ascenzo F; Frati G; Mancone M; Genereux P; Stone GW
J Am Coll Cardiol; 2014 Feb; 63(4):299-307. PubMed ID: 24211507
[TBL] [Abstract][Full Text] [Related]
11. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: conceptual evolution based on emerging evidence.
Palmerini T; Stone GW
Eur Heart J; 2016 Jan; 37(4):353-64. PubMed ID: 26795933
[TBL] [Abstract][Full Text] [Related]
12. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Bittl JA; Baber U; Bradley SM; Wijeysundera DN
J Am Coll Cardiol; 2016 Sep; 68(10):1116-39. PubMed ID: 27036919
[TBL] [Abstract][Full Text] [Related]
13. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials.
Giustino G; Baber U; Sartori S; Mehran R; Mastoris I; Kini AS; Sharma SK; Pocock SJ; Dangas GD
J Am Coll Cardiol; 2015 Apr; 65(13):1298-1310. PubMed ID: 25681754
[TBL] [Abstract][Full Text] [Related]
14. Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials.
Ziada KM; Abdel-Latif AK; Charnigo R; Moliterno DJ
Catheter Cardiovasc Interv; 2016 Mar; 87(4):722-732. PubMed ID: 26309050
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials.
Garg A; Rout A; Sharma A; Sargsyan D; Beavers T; Tantry U; Gurbel P; Rao SV; Kostis JB; Cohen M
Prog Cardiovasc Dis; 2020; 63(3):243-248. PubMed ID: 32247786
[TBL] [Abstract][Full Text] [Related]
16. Meta-Analysis of the Duration of Dual Antiplatelet Therapy in Patients Treated With Second-Generation Drug-Eluting Stents.
D'Ascenzo F; Moretti C; Bianco M; Bernardi A; Taha S; Cerrato E; Omedè P; Montefusco A; Frangieh AH; Lee CW; Campo G; Chieffo A; Quadri G; Pavani M; Zoccai GB; Gaita F; Park SJ; Colombo A; Templin C; Lüscher TF; Stone GW
Am J Cardiol; 2016 Jun; 117(11):1714-23. PubMed ID: 27134057
[TBL] [Abstract][Full Text] [Related]
17. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial.
Colombo A; Chieffo A; Frasheri A; Garbo R; Masotti-Centol M; Salvatella N; Oteo Dominguez JF; Steffanon L; Tarantini G; Presbitero P; Menozzi A; Pucci E; Mauri J; Cesana BM; Giustino G; Sardella G
J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2086-97. PubMed ID: 25236346
[TBL] [Abstract][Full Text] [Related]
18. Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODIGY trial.
Crimi G; Leonardi S; Costa F; Adamo M; Ariotti S; Valgimigli M
Int J Cardiol; 2016 Jun; 212():110-7. PubMed ID: 27038714
[TBL] [Abstract][Full Text] [Related]
19. Stent thrombosis with drug-eluting stents: is the paradigm shifting?
Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Genereux P; Branzi A; Stone GW
J Am Coll Cardiol; 2013 Nov; 62(21):1915-1921. PubMed ID: 24036025
[TBL] [Abstract][Full Text] [Related]
20. Optimal duration of dual antiplatelet therapy after second-generation drug-eluting stent implantation in patients with diabetes: The SECURITY (Second-Generation Drug-Eluting Stent Implantation Followed By Six- Versus Twelve-Month Dual Antiplatelet Therapy)-diabetes substudy.
Tarantini G; Nai Fovino L; Tellaroli P; Chieffo A; Barioli A; Menozzi A; Frasheri A; Garbo R; Masotti-Centol M; Salvatella N; Dominguez JF; Steffanon L; Presbitero P; Pucci E; Fraccaro C; Mauri J; Giustino G; Sardella G; Colombo A
Int J Cardiol; 2016 Mar; 207():168-76. PubMed ID: 26803236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
